2025-05-14T13:27:53-05:00 2024-06-30 814234542 BPM LLP 10 ALMADEN BOULEVARD SUITE 1000 SAN JOSE CA 951132238 990 2023-07-01 453266802 CANCER COMMONS CANC 6502894044 2625 MIDDLEFIELD ROAD 104 PALO ALTO CA 94306 JAY M TENENBAUM PRESIDENT, CHAIRMAN, AND DIRECTOR 6502894044 2025-05-09 1 1 TAMARA L MCINERNEY P00011797 4089616300 2025-05-09 2023 2025-03-06 01:10:19Z JAY M TENENBAUM 2625 MIDDLEFIELD ROAD 104 PALO ALTO CA 94306 1336687 0 X WWW.CANCERCOMMONS.ORG X 2011 CA CANCER COMMONS IS A NON-PROFIT NETWORK OF PATIENTS, SCIENTISTS, AND PHYSICIANS UNITED BY A SHARED GOAL TO OPTIMIZE EACH PATIENT'S OUTCOME AND MAXIMIZE COLLECTIVE LEARNING TO BENEFIT THE NEXT PATIENT. 6 6 8 4 0 0 1170687 1247340 58820 0 2704 -653 -67867 0 1164344 1246687 0 0 0 0 1207447 708604 0 0 128912 375398 462832 1582845 1171436 -418501 75251 408611 517762 57012 90912 351599 426850 X CANCER COMMONS IS A NON-PROFIT NETWORK OF PATIENTS, SCIENTISTS, AND PHYSICIANS UNITED BY A SHARED GOAL TO OPTIMIZE EACH PATIENT'S OUTCOME AND MAXIMIZE COLLECTIVE LEARNING TO BENEFIT THE NEXT PATIENT. 0 0 792502 0 PATIENT NAVIGATION AND SUPPORT:CANCER COMMONS HELPS PATIENTS UNDERSTAND THEIR DIAGNOSIS AND IDENTIFY THEIR BEST TREATMENT OPTIONS, COMBINING COMPASSION WITH DEEP SCIENTIFIC KNOWLEDGE.PROVIDED PERSONALIZED GUIDANCE TO MORE THAN 1,100 PATIENTS AND CAREGIVERS IN FY2024, ASSISTED INDIVIDUALS WITH OVER 35 DIFFERENT CANCER TYPES. MANY SOUGHT SUPPORT FOR ADVANCED, HARD-TO-TREAT CANCERS, INCLUDING MORE THAN 300 WITH BRAIN CANCER AND NEARLY 150 WITH PANCREATIC CANCER.PATIENT NAVIGATORS FACILITATE REGISTRATION, ASSIST IN IDENTIFYING TREATMENT GOALS, AND COLLECT MEDICAL RECORDS TO STREAMLINE ACCESS TO EXPERT GUIDANCE AND VIABLE TREATMENT OPTIONS.ADDITIONAL SERVICES:. COMPREHENSIVE TREATMENT REVIEWS - CONDUCTS IN-DEPTH TREATMENT REVIEWS TAILORED TO EACH PATIENT'S NEEDS, WHICH MAY INCLUDE ASSESSMENTS OF CLINICAL TRIAL ELIGIBILITY OR RECOMMENDATIONS FOR OFF-LABEL TREATMENT OPTIONS. ALL GUIDANCE IS GROUNDED IN THE LATEST RESEARCH, BEST PRACTICES, AND MEDICAL DATA.. PRECISION ONCOLOGY EXPERTISE - ANALYZES DATA FROM CUTTING-EDGE MOLECULAR PROFILING, LIQUID BIOPSY, AND FUNCTIONAL PRECISION MEDICINE DRUG SCREENING. THEIR STAFF SCIENTISTS AND EXTERNAL EXPERTS USE THIS INFORMATION TO RECOMMEND TARGETED THERAPIES WITH THE HIGHEST POTENTIAL FOR SUCCESS.. ONGOING SUPPORT THE TEAM REMAINS COMMITTED TO PATIENTS BEYOND THE INITIAL RECOMMENDATIONS. THE ORGANIZATION PROVIDES PERIODIC REVIEWS AND UPDATES, ACCOUNTING FOR CHANGES IN DISEASE STATUS, EMERGING RESEARCH, AND NEWLY AVAILABLE TREATMENTS. THEIR TEAM CONTINUES TO ENGAGE WITH PATIENTS, ADAPTING CARE PLANS THROUGHOUT EACH PATIENT'S JOURNEY TO ACHIEVE OPTIMAL OUTCOMES. 91590 PARTNERSHIPS:CANCER COMMONS COLLABORATES WITH ORGANIZATIONS THAT SHARE ITS PATIENT-FOCUSED APPROACH TO CANCER CARE. THROUGH A PARTNERSHIP WITH XCURES, CANCER COMMONS PATIENTS ARE INVITED TO ENROLL IN XCELSIOR, A PLATFORM TRIAL THAT INTEGRATES PRECISION ONCOLOGY INSIGHTS WITH CUTTINGEDGE TECHNOLOGY TO OFFER INNOVATIVE TREATMENT OPPORTUNITIES.CANCER COMMONS ALSO MAINTAINS PARTNERSHIPS WITH INSTITUTIONS AND ORGANIZATIONS SUPPORTING PATIENTS WITH COMPLEX CANCER CASES. THESE ENTITIES EITHER REFER PATIENTS NEEDING EXPERT GUIDANCE OR PROVIDE SPECIALIZED SERVICES DIRECTLY. KEY PARTNERSHIPS IN FY2024 INCLUDED THE MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION AND HEAD FOR THE CURE. 29530 LEARNING HEALTH SYSTEM DEVELOPMENT:CANCER COMMONS DEVELOPED A PROTOTYPE LEARNING HEALTH SYSTEM (LHS) SOFTWARE AIMED AT ADVANCING TREATMENT RECOMMENDATIONS THROUGH TECHNOLOGY. THE SYSTEM IS DESIGNED TO COMBINE REAL-WORLD PATIENT DATA AND AI ANALYSIS TO HELP REFINE DECISION-MAKING AND ASSIST ONCOLOGISTS IN IDENTIFYING OPTIMAL TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED CANCERS.THIS DEMO VERSION OF THE LHS WAS DESIGNED TO PROCESS AND ANALYZE PATIENT CASES, ASSESSING ITS POTENTIAL TO SPEED UP DECISION-MAKING AND PROVIDE ONCOLOGISTS WITH USEFUL, DATA-DRIVEN INSIGHTS. THESE EFFORTS LAY THE FOUNDATION FOR A MORE EFFICIENT CASE REVIEW PROCESS WITH THE GOAL OF EXPANDING CANCER COMMONS' ABILITY TO SUPPORT MORE PATIENTS AND CONTRIBUTE VALUABLE INSIGHTS TO CANCER RESEARCH AND CARE. 913622 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 16 0 1 8 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X MARTHA DEHNOW 6505303636 2625 MIDDLEFIELD ROAD SUITE 104 PALO ALTO CA 94306 X JAY M TENENBAUM FOUNDER AND CHAIRMAN 20.00 X X 0 0 0 PAUL BILLINGS VICE CHAIR 1.00 X 0 0 0 LARRY MARTON BOARD MEMBER 1.00 X 0 0 0 VERN NORVIEL BOARD MEMBER 1.00 X 0 0 0 GREG SIMON BOARD MEMBER (FROM 8/24/23) 1.00 X 0 0 0 BILL STASIOR BOARD MEMBER (FROM 10/25/23) 1.00 X 0 0 0 GLADYS MONROY BOARD MEMBER (THRU 4/14/2024) 1.00 X 0 0 0 ED STAREN BOARD MEMBER (THRU 9/28/23) 1.00 X 0 0 0 MASAKO YOKOTA CHIEF OF STAFF 40.00 X 79858 0 35441 SHELLEY FRISBIE CFO 25.00 X 113150 0 0 KAMUDI BHAWE SENIOR SCIENTIST 40.00 X 120857 0 22831 ADRIENNE NUGENT DIRECTOR OF SCIENTIFIC & CLINICAL OPERATIONS 40.00 X 143333 0 253 457198 0 58525 3 0 0 0 THE SHELLARD GROUP 1325 HOWARD AVE 944 BURLINGAME CA 94010 ACTING CFO/FINANCIAL 113150 1 1247340 89775 1247340 3146 3146 86201 90000 -3799 -3799 -3799 1246687 0 0 -653 X 263917 219043 21118 23756 323779 286593 4373 32813 75078 60814 4600 9664 45830 39670 1866 4294 7526 5000 2526 90395 17135 61249 12011 307917 262707 7710 37500 14432 2604 9936 1892 14108 4361 3884 5863 2943 1500 324 1119 504 504 15155 6191 8964 MEMBERSHIP DUES 5000 5000 OTHER COSTS 2500 2500 PROGRAM SERVICE FEES 1622 1622 LSTE FEES & PENALITIES 510 510 220 220 1171436 913622 128902 128912 134178 498835 255352 6000 17081 10927 1196 1196 0 0 2000 2000 408611 517762 57012 90912 57012 90912 X 329703 166850 21896 260000 351599 426850 408611 517762 75251 0 X 0 0 0 X 2103518 1733265 1629304 1104278 1247340 7817705 2103518 1733265 1629304 1104278 1247340 7817705 2857225 4960480 23 3156 3179 868 6329 322 2622 10141 7831025 84553 0.63340 0.60350 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1196 1196 0 0 X 1 89775 FMV 0 0 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS GIVEN TO THE GOVERNING BODY BEFORE THE RETURN IS FILED. THEY REVIEW AND CAN REQUEST CHANGES AT THIS TIME. FORM 990, PART VI, SECTION B, LINE 12C THE OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO REVIEW AND SIGN THE WRITTEN CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS PERFORMS ALL INTERVIEWS SPECIFIC TO TOP KEY POSITIONS WHICH IS THEN FORWARDED TO THE FULL BOARD OF DIRECTORS FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 MADE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION B, LINE 1: EMILYA SHTIVELMAN'S COMPENSATION REPORTED ON PART VII, SECTION B IS INCLUDED IN THE AMOUNTS ON PART VII, SECTION A. FORM 990, PART IX, LINE 11G OTHER CONSULTING COSTS: PROGRAM SERVICE EXPENSES 262,707. MANAGEMENT AND GENERAL EXPENSES 7,710. FUNDRAISING EXPENSES 37,500. TOTAL EXPENSES 307,917.